ATLANTA, GA – – (Globe Newswire – January 6, 2025) – – A shareholder class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC). The lawsuit alleges that Defendants made materially false and/or misleading statements, and/or failed to disclose material adverse facts about Revance’s business, operations, and prospects, including allegations that: (i) Revance was in material breach of its distribution agreement with Teoxane SA; (ii) the foregoing subjected Revance to an increased risk of litigation, as well as monetary and reputational harm; and (iii) all the foregoing increased the risk that Crown Laboratories, Inc.’s tender offer to acquire all outstanding shares of the Company’s common stock would be delayed and/or amended.

If you bought shares of Revance between February 29, 2024 and December 6, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/revance-therapeutics/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is March 4, 2025.